Susquehanna International Group, LLP Vaxcyte, Inc. Call Options Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$70.52 - $117.12 $345,548 - $573,888	-4,900 Reduced 3.87%	121,600 $13.9 Million
Q2 2024 Aug 15, 2024	BUY	$60.06 - $78.77 $4.26 Million - $5.59 Million	71,000 Added 127.93%	126,500 $9.55 Million
Q1 2024 May 07, 2024	BUY	$59.79 - $81.05 $101,643 - $137,785	1,700 Added 3.16%	55,500 $3.79 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $1.82 Million - $2.55 Million	40,200 Added 295.59%	53,800 $3.38 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $423,200 - $488,520	-9,200 Reduced 40.35%	13,600 $693,000
Q2 2023 Aug 11, 2023	SELL	$34.66 - $54.07 $1.93 Million - $3.01 Million	-55,600 Reduced 70.92%	22,800 $1.14 Million
Q1 2023 May 16, 2023	SELL	$36.27 - $47.2 $3.56 Million - $4.64 Million	-98,200 Reduced 55.61%	78,400 $2.94 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $2.14 Million - $5 Million	104,200 Added 143.92%	176,600 $8.47 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $503,208 - $661,896	23,200 Added 47.15%	72,400 $1.74 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $525,096 - $789,426	29,700 Added 152.31%	49,200 $1.07 Million
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $185,076 - $279,416	10,600 Added 119.1%	19,500 $471,000
Q4 2021 Feb 14, 2022	SELL	$19.32 - $26.45 $59,892 - $81,995	-3,100 Reduced 25.83%	8,900 $212,000
Q3 2021 Nov 15, 2021	SELL	$20.26 - $26.97 $95,222 - $126,759	-4,700 Reduced 28.14%	12,000 $304,000
Q1 2021 May 17, 2021	BUY	$18.66 - $29.16 $311,622 - $486,972	16,700 New	16,700 $330,000

353

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.94B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.